top of page

Supply issue: teriparatide inj 250 mcg per ml, 2.4 ml (Teva)

  • 5 hours ago
  • 1 min read

Supply Issue:

 

We are writing to inform you that the supplier Teva has advised Pharmac that it is unable to provide teriparatide injection. Pharmac are listing an alternate product.

 

Key Dates:

  • The Teva brand will be unavailable from the end of February 2026. The resupply date is not yet confirmed.

  • An alternative - Forteo brand will be listed (funded) on the Pharmaceutical Schedule from 1 March 2026

 

Key messages:

  • The Forteo brand was previously supplied to the New Zealand market from 2011 to 2024.

  • This Forteo product is supplied to the USA market.

  • The pen device contains the same 28 doses, at the same strength and has the same mechanism as the current Teva product, and previously supplied Forteo product.

  • The USA product has slightly different labelling to the prior Forteo product, and is not Medsafe approved, so will need to be supplied in line with S29A of the Medicines Act.

  • Images and more information can be seen on our webpage - Teriparatide inj on Pharmac website 

  • Our webpage includes a downloadable patient information leaflet.

 

Questions: 

If you have any queries, please contact us at enquiry@pharmac.govt.nz

 

Please share this information:

Please share this information with your colleagues and within your networks.


Ngā mihi,

 

Anna I Senior Advisor Implementation

Pharmac | Te Pātaka Whaioranga | PO Box 10

254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz



bottom of page